Targeting Myeloid Derived Suppressor Cells enhances the response of immune checkpoint inhibitor
Year: 2017
Type: dissertation
Abstract: Myeloid derived suppressor cells (MDSC) are a heterogeneous population of early myeloid cells that expand in tumor-bearing hosts in response to soluble factors produced by tumor and stromal cells. MDSC play a critical role during tumor evasion and have been linked to loss of immune effector cell function through variety of mechanisms such as the generation of reactive oxygen and nitrogen species (ROS and RNS) and cytokines. Ibrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and IL2-inducible T-cell kinase (ITK), is in clinical use for the treatment of B-cell malignancies. Tumors express immune-checkpoint molecules including programmed death ligand 1 (PD-L1) to escape immune destruction. PD-L1 binds to its receptor, programmed cell death protein 1 (PD-1), which inhibits the function of T cells. Anti-PD-L1 monoclonal antibody prevents the engagement of the PDL1 to its receptor. This study was designed to investigate the effect of ibrutinib and/or an anti-PD-L1 antibody on tumor growth and the levels of MDSC using a mouse model of melanoma. C57BL/6 mice were inoculated with 1x105 B16F1 melanoma cells. Mice were treated with either vehicle, ibrutinib (12.5 mg/kg) via drinking water, anti-PD-L1 (25 µg) antibody i.p injected three times a week, or a combination. Tumors were measured three times a week using digital calipers. Our results show that ibrutinib and anti-PD-L1 Ab treatment had a modest effect on tumor growth, while the combination treatment had a 32% reduction. Mice treated with ibrutinib, anti-PD-L1 ab or a combination had MDSC level in the spleen of 6.57%, 5.64%, and 5.46% respectively, compared to the vehicle’s 8.58%. These results show a modulation in ibrutinib can reduce the levels of MDSC in tumor bearing mice, and reveals potential strategy for enhancing the anti-tumor response of anti-PD-L1 by combination with ibrutinib.
Author: Abood, David
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7034426430
